Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: A report from the International DLBCL Rituximab-CHOP Consortium Program

Blood

Volumn 121, Issue 22, 2013, Pages 4529-4540

  Li, Yong ^a,b   Gordon, Michael W ^a   Xu Monette, Zijun Y ^b   Visco, Carlo ^c   Tzankov, Alexander ^d   Zou, Dehui ^e   Qiu, Lugui ^e   Montes Moreno, Santiago ^f   Dybkaer, Karen ^g   Orazi, Attilio ^h   Zu, Youli ⁱ   Bhagat, Govind ^j   Richards, Kristy L ^k   Hsi, Eric D ^l   Choi, William W L ^m   Van Krieken, J Han ⁿ   Huang, Qin ^o   Ai, Weiyun ^p   Ponzoni, Maurilio ^q   Ferreri, Andrés J M ^q   Winter, Jane N ^r   Go, Ronald S ^s   Piris, Miguel A ^f   Møller, Michael B ^t   Wu, Lin ^u   Wang, Michael ^b   Ramos, Kenneth S ^a   Medeiros, L Jeffrey ^b   Young, Ken H ^b   more..

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SAN BORTOLO HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^f HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁱ HOUSTON METHODIST HOSPITAL   (United States)

^j Columbia University School of Medicine ^*  (United States)

^k UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^l LERNER RESEARCH INSTITUTE   (United States)

^m UNIVERSITY OF HONG KONG   (Hong Kong)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q SAN RAFFAELE HOSPITAL   (Italy)

^r NORTHWESTERN UNIVERSITY   (United States)

^s GUNDERSEN LUTHERAN MEDICAL CENTER   (United States)

^t ODENSE UNIVERSITY HOSPITAL   (Denmark)

^u ROCHE MOLECULAR SYSTEMS   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MICRORNA 125B; PREDNISONE; PROTEIN P53; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MICRORNA; MONOCLONAL ANTIBODY; TP53 PROTEIN, HUMAN;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DOWN REGULATION; GENE SEQUENCE; GERMLINE MUTATION; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POLYADENYLATION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SURVIVAL RATE; 5' UNTRANSLATED REGION; GENETIC SCREENING; GENETICS; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MORTALITY; MUTATION; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; 5' UNTRANSLATED REGIONS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICRORNAS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREDNISONE; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

MLCS; MLOWN;

EID: 84880857890     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-12-471722     Document Type: Article

References (50)

1. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661-665.
2. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007;445(7128):656-660.
3. Whibley C, Pharoah PDP, Hollstein M. p53 polymorphisms: cancer implications. Nat Rev Cancer. 2009;9(2):95-107.
4. Palmero EI, Achatz MI, Ashton-Prolla P, Olivier M, Hainaut P. Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Curr Opin Oncol. 2010;22(1):64-69.
5. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2(2):a001107.
6. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119(6): 847-860.
7. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-872.
8. Storey A, Thomas M, Kalita A, et al. Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature. 1998; 393(6682):229-234.
9. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362(15):1417-1429.
10. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol. 2011;29(14): 1803-1811.
11. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
12. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
13. Lohr JG, Stojanov P, Lawrence MS, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA. 2012;109(10):3879-3884.
14. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
15. Vogelstein B, Sur S, Prives C. p53: the most frequently altered gene in human cancers. Nature Education. 2010;3(9):6.
16. Young KH, Leroy K, Møller MB, et al. Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood. 2008; 112(8):3088-3098.
17. Xu-Monette ZY, Wu L, Visco C, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986-3996.
18. Lu Z, Li Y, Takwi A, et al. miR-301a as an NF-kB activator in pancreatic cancer cells. EMBO J. 2011;30(1):57-67.
19. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.
20. Kumar M, Lu Z, Takwi AAL, et al. Negative regulation of the tumor suppressor p53 gene by microRNAs. Oncogene. 2011;30(7):843-853.
21. Le MTN, Teh C, Shyh-Chang N, et al. MicroRNA-125b is a novel negative regulator of p53. Genes Dev. 2009;23(7):862-876.
22. Hu W, Chan CS, Wu R, et al. Negative regulation of tumor suppressor p53 by microRNA miR-504. Mol Cell. 2010;38(5):689-699.
23. Swarbrick A, Woods SL, Shaw A, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med. 2010;16(10):1134-1140.
24. Neveu P, Kye MJ, Qi S, et al. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell. 2010;7(6): 671-681.
25. Becker LE, Lu Z, Chen W, Xiong W, Kong M, Li Y. A systematic screen reveals MicroRNA clusters that significantly regulate four major signaling pathways. PLoS ONE. 2012;7(11):e48474.
26. Tian S, Huang S, Wu S, Guo W, Li J, He X. MicroRNA-1285 inhibits the expression of p53 by directly targeting its 39 untranslated region. Biochem Biophys Res Commun. 2010;396(2): 435-439.
27. Fabbri M, Bottoni A, Shimizu M, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011;305(1):59-67.
28. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92-105.
29. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136(2):215-233.
30. Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011;43(11):1098-1103.
31. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell. 2009;138(4):673-684.
32. Topisirovic I, Siddiqui N, Orolicki S, et al. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol. 2009;29(5): 1152-1162.
33. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
34. Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol. 2008;8(1):22-33.
35. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006;34(Database issue suppl 1):D617-D621.
36. Stacey SN, Sulem P, Jonasdottir A, et al. Swedish Low-risk Colorectal Cancer Study Group. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. Nat Genet. 2011;43(11):1098-1103.
37. Monti S, Chapuy B, Takeyama K, et al. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. Cancer Cell. 2012;22(3):359-372.
38. Landgraf P, Rusu M, Sheridan R, et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell. 2007;129(7): 1401-1414.
39. Petriv OI, Kuchenbauer F, Delaney AD, et al. Comprehensive microRNA expression profiling of the hematopoietic hierarchy. Proc Natl Acad Sci USA. 2010;107(35):15443-15448.
40. Spierings DC, McGoldrick D, Hamilton-Easton AM, et al. Ordered progression of stage-specific miRNA profiles in the mouse B2 B-cell lineage. Blood. 2011; 117(20):5340-5349.
41. Zhang J, Jima DD, Jacobs C, et al. Patterns of microRNA expression characterize stages of human B-cell differentiation. Blood. 2009;113(19): 4586-4594.
42. Malumbres R, Sarosiek KA, Cubedo E, et al. Differentiation stage-specific expression of microRNAs in B lymphocytes and diffuse large B-cell lymphomas. Blood. 2009;113(16): 3754-3764.
43. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005;123(1):49-63.
44. Mazan-Mamczarz K, Galbán S, López de Silanes I, et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA. 2003; 100(14):8354-8359.
45. Chng WJ. Genetic abnormalities in multiple myeloma. In: Kumar S, Abraham J, eds. Multiple Myeloma. New York, NY: Demos Medical Publishing; 2010:215-236.
46. Thomas DC, Haile RW, Duggan D. Recent developments in genomewide association scans: a workshop summary and review. Am J Hum Genet. 2005;77(3):337-345.
47. Zhou L, Yuan Q, Yang M. A functional germline variant in the P53 polyadenylation signal and risk of esophageal squamous cell carcinoma. Gene. 2012;506(2):295-297.
48. Egan KM, Nabors LB, Olson JJ, et al. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet. 2012;49(7):420-421.
49. Wickens M, Stephenson P. Role of the conserved AAUAAA sequence: four AAUAAA point mutants prevent messenger RNA 39 end formation. Science. 1984;226(4678):1045-1051.
50. Zarkower D, Stephenson P, Sheets M, Wickens M. The AAUAAA sequence is required both for cleavage and for polyadenylation of simian virus 40 pre-mRNA in vitro. Mol Cell Biol. 1986;6(7): 2317-2323.